Integrin alpha V beta 3 together with alpha IIb beta 3, constitutes the only known beta 3 Integrins (1‑3). The non‑covalent heterodimer of 170 kDa alpha V/CD51 and 93 kDa beta 3/CD61 subunits shows wide expression, notably by endothelial cells and osteoclasts (2‑4). Each subunit has a transmembrane sequence and a short cytoplasmic tail connected to the cytoskeleton. Active cell surface alpha V beta 3 adheres to matrix proteins including vitronectin, fibronectin, fibrinogen and thrombospondin (2, 3). The ligand binding site of alpha V beta 3 is in the N‑terminal head region, formed by interaction of the beta 3 vWFA domain with the alpha V beta‑propeller structure (4). The alpha V subunit contributes a thigh and a calf region, while the beta 3 subunit contains a PSI domain and four cysteine‑rich I‑EGF folds. The alpha V subunit domains termed thigh, calf‑1 and calf‑2 generate a “knee” region that is bent when the alpha V beta 3 is in its constitutively inactive state. Activation, either by “inside out” signaling or by Mg2+ or Mn2+ binding, extends the Integrin to expose its ligand binding site (1, 4). The 962 aa human alpha V ECD(11) shares 92‑95% aa sequence identity with mouse, rat and bovine alpha V while the 685 aa human beta 3 ECD(12) shares 95% aa identity with equine and canine, and 89‑92% aa identity with mouse, rat and porcine beta 3. Two splice variants of beta 3 (b and c) diverge over the last 21 amino acids (aa) and lack cytoplasmic phosphorylation sites (5, 6). Another beta 3 splice variant diverges after the vWFA domain, producing a soluble 60 kDa form in platelets and endothelial cells (7). alpha V beta 3 is essential for the maturation of osteoclasts and their binding and resorption of bone; it also, however, promotes their apoptosis (8, 9). M‑CSF R and alpha V beta 3 share signaling pathways during osteoclastogenesis, and deletion of either molecule causes osteopetrosis (8, 9). alpha V beta 3 is involved in several other signaling pathways by direct interaction with receptor tyrosine kinases and ligands. For example, it cooperates with endothelial cell VEGF R2 in angiogenesis, and with IGF‑1 to promote cancer cell proliferation and invasiveness (13, 14). Also, cell entry of several viruses is mediated by alpha V beta 3 (4, 10).
Recombinant Human Integrin alpha V beta 3 Protein, CF
R&D Systems | Catalog # 3050-AV
Key Product Details
- R&D Systems CHO-derived Recombinant Human Integrin alpha V beta 3 Protein (3050-AV)
- Quality control testing to verify active proteins with lot specific assays by in-house scientists
- All R&D Systems proteins are covered with a 100% guarantee
Source
Accession Number
Applications
Product Specifications
Source
| Human Integrin alpha V subunit (Phe31-Val992) Accession # NP_002201 |
His-Pro | GGGSGGGS | Acidic Tail |
| Human Integrin beta 3 subunit (Gly27-Asp718) Accession # AAA52589 |
His-Pro | GGGSGGGS | Basic Tail |
| N-terminus | C-terminus | ||
Purity
Endotoxin Level
N-terminal Sequence Analysis
Predicted Molecular Mass
SDS-PAGE
Activity
Measured by its binding ability in a functional ELISA.
Immobilized Recombinant Human Vitronectin (Catalog # 2308-VN) at 1 µg/mL can bind Recombinant Human Integrin alpha V beta 3 with an apparent KD <10 nM.
Reviewed Applications
Read 2 reviews rated 4 using 3050-AV in the following applications:
Formulation, Preparation, and Storage
3050-AV
| Formulation | Lyophilized from a 0.2 μm filtered solution in Tris, NaCl and CaCl2. |
| Reconstitution | Reconstitute at 100 μg/mL in sterile PBS.
Loading...
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Calculators
Background: Integrin alpha V beta 3
References
- Hynes, R. O. (2002) Cell 110:673.
- Serini, G. et al. (2006) Exp. Cell Res. 312:651.
- Ross, F. P. and S. L. Teitelbaum (2005) Immunol. Rev. 208:88.
- Xiong, J. et al. (2001) Science 294:339.
- Kumar, C. S. et al. (1987) J. Biol. Chem. 272:16390.
- vanKuppevelt, H. et al. (1989) Proc. Natl. Acad. Sci. USA 86:5415.
- Djaffar, I. et al. (1994) Biochem. J. 300:69.
- McHugh, K. P. et al. (2000) J. Clin. Invest. 105:433.
- Faccio, R. et al. (2003) J. Clin. Invest. 111:749.
- Chu, J. J. and M. Ng (2004) J. Biol. Chem. 279:54533.
- Suzuki, S. et al. (1987) J. Biol. Chem. 262:14060.
- Fitzgerald, L. A. et al. (1987) J. Biol. Chem. 262:3936.
- Somanath, P.R. et al. (2009) Angiogenesis 12:177.
- Saegusa, J. et al. (2009) J. Biol. Chem. 284:24106.
Alternate Names
Entrez Gene IDs
Gene Symbol
Additional Integrin alpha V beta 3 Products
Product Documents for Recombinant Human Integrin alpha V beta 3 Protein, CF
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Note: Certificate of Analysis not available for kit components.
Product Specific Notices for Recombinant Human Integrin alpha V beta 3 Protein, CF
For research use only
Citations for Recombinant Human Integrin alpha V beta 3 Protein, CF
Powered by Bioz
Customer Reviews for Recombinant Human Integrin alpha V beta 3 Protein, CF (2)
Have you used Recombinant Human Integrin alpha V beta 3 Protein, CF?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 Yen for a review with an image
$10/€7/£6/$10CAN/¥1110 Yen for a review without an image
Submit a review
Customer Images
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 05/04/2020
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 05/18/2016Integrin avb3 we purchased was good, but they wouldn't separate on reducing gel, the heterodimer remain strongly intact. I have used for binding assays, and in SPR it worked very well. traces of calcium might be present which inhibits integrin avb3 but has to be washed completely removing those ions.
There are no reviews that match your criteria.
FAQs for Recombinant Human Integrin alpha V beta 3 Protein, CF
-
Q: What is the amino acid sequence of the acidic and basic tails?
A: Acidic and basic tails are added to the protein to help facilitate optimal activity. While we generally include sequence information on the product datasheet, the sequences of these tails are considered confidential information.
